William Blair Upgrades Biodesix After Beats, Guides 23% Revenue Growth to $106–$112M
William Blair upgraded Biodesix from Market Perform to Outperform after the company reported a $0.49 per share loss versus a $1.05 expected loss and delivered $28.76 million in revenue, 14.11% above estimates. Biodesix achieved 41% year-over-year revenue growth, posted its first adjusted EBITDA positivity and guided fiscal 2026 revenue to $106–$112 million (23% growth).
1. Stock Upgrade
On February 27, William Blair raised Biodesix from Market Perform to Outperform, highlighting the company’s improved financial metrics following stronger loss and revenue results in the latest quarter.
2. Quarterly Financial Results
Biodesix reported a $0.49 per share loss versus an expected $1.05 loss and achieved $28.76 million in revenue, 14.11% above consensus and up from $20.43 million a year ago, delivering an 83% gross margin and 41% year-over-year revenue growth.
3. Adjusted EBITDA Positivity and Guidance
The company narrowed its net loss by 52%, recorded its first adjusted EBITDA positivity, and issued fiscal 2026 revenue guidance of $106–$112 million, implying 23% growth at the midpoint.
4. Market Reaction and Trading Metrics
Shares jumped 9.98% to close at $14.22, trading between $12.36 and $14.22, with a market capitalization of $113.13 million and 120,970 shares changing hands.